Home
PRAX
PRAX News

Latest Praxis Precision Medicines Inc. (PRAX) News on August 17, 2025

Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX)

Insider Monkey

2 months ago

Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Energy Global

2 months ago

TPG Rise Climate acquires Aurora Energy Research

GlobeNewswire

2 months ago

Form 8.3 - Assura Plc

BAE Systems awarded $30 million from U.S. Navy for Identification Friend or Foe AN/APX-123A(V) Common Transponder

PR Newswire

2 months ago

BAE Systems awarded $30 million from U.S. Navy for Identification Friend or Foe AN/APX-123A(V) Common Transponder

Media Advisory – Canada’s food workers union sues Health Canada over pesticide safety failures

GlobeNewswire

2 months ago

Media Advisory – Canada’s food workers union sues Health Canada over pesticide safety failures

Business Wire

2 months ago

Net Asset Value(s)

Makera Wins Desktop CNC Machine Company of the Year Award

PR Newswire

2 months ago

Makera Wins Desktop CNC Machine Company of the Year Award

US Federal Reserve lifts Wells Fargo’s asset cap

Retail Banker International

2 months ago

US Federal Reserve lifts Wells Fargo’s asset cap

PEEK (Glass Filled, Carbon Filled, Unfilled) Markets - Global Forecast to 2030 with Victrex, Syensqo, Evonik Industries, Jilin Joinature Polymer, and Junhua Leading

GlobeNewswire

2 months ago

PEEK (Glass Filled, Carbon Filled, Unfilled) Markets - Global Forecast to 2030 with Victrex, Syensqo, Evonik Industries, Jilin Joinature Polymer, and Junhua Leading

Ulta Stock Jumps as Beauty Product Spending Continues

Investopedia

3 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

GlobeNewswire

3 months ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

GlobeNewswire

3 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt

Benzinga

3 months ago

Northrop Grumman Raises $1 Billion Via Debt

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

GlobeNewswire

3 months ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

Newsfile

3 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

GlobeNewswire

3 months ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

The York Water Company Files a Rate Request Based on $145 Million in Investment

GlobeNewswire

3 months ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

Praxis Precision Medicines to Participate in Upcoming Conferences

GlobeNewswire

3 months ago

Praxis Precision Medicines to Participate in Upcoming Conferences

MT Newswires

3 months ago

Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target

MT Newswires

3 months ago

Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

GlobeNewswire

3 months ago

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

Simply Wall St.

3 months ago

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

GlobeNewswire

3 months ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

GlobeNewswire

4 months ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines to Participate in Upcoming April Conferences

GlobeNewswire

4 months ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Simply Wall St.

5 months ago

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire

5 months ago

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision price target lowered to $85 from $150 at Needham

TipRanks

5 months ago

Praxis Precision price target lowered to $85 from $150 at Needham

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

GlobeNewswire

5 months ago

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

MT Newswires

5 months ago

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

MT Newswires

6 months ago

Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall

MT Newswires

6 months ago

Top Midday Decliners

MT Newswires

6 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

MT Newswires

6 months ago

Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

Zacks

6 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

6 months ago

Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

GlobeNewswire

6 months ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

6 months ago

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

6 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

MT Newswires

6 months ago

Deutsche Bank Initiates Coverage on Praxis Precision Medicines With Buy Rating, $111 Price Target

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Present at Two February Investor Conferences

GlobeNewswire

6 months ago

Praxis Precision Medicines to Present at Two February Investor Conferences

MT Newswires

7 months ago

Truist Securities Adjusts Price Target on Praxis Precision Medicines to $175 From $150, Keeps Buy Rating

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

GlobeNewswire

7 months ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

GlobeNewswire

7 months ago

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

MT Newswires

8 months ago

Praxis Precision Medicines Files for Mixed Shelf, $250 Million Common Stock Sale

MT Newswires

8 months ago

Praxis Says FDA Grants Rare Pediatric Disease Designation to Relutrigine to Treat Dravet Syndrome

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

GlobeNewswire

8 months ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

GlobeNewswire

8 months ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

GlobeNewswire

9 months ago

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...

GuruFocus.com

9 months ago

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

GlobeNewswire

9 months ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

MT Newswires

9 months ago

Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating

MT Newswires

9 months ago

Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Zacks

9 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire

9 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

GlobeNewswire

10 months ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Simply Wall St.

10 months ago

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Health Care Roundup: Market Talk

The Wall Street Journal

10 months ago

Health Care Roundup: Market Talk

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals

Insider Monkey

10 months ago

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

Zacks

10 months ago

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

GlobeNewswire

a year ago

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

GuruFocus.com

a year ago

Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Zacks

a year ago

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

GlobeNewswire

a year ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

MT Newswires

a year ago

Wedbush Adjusts Price Target on Praxis Precision Medicines to $51 From $48, Maintains Neutral Rating

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Benzinga

a year ago

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

GlobeNewswire

a year ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

GlobeNewswire

a year ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a year ago

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Zacks

a year ago

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

MT Newswires

a year ago

Oppenheimer Starts Praxis Precision Medicines With Outperform Rating, $134 Price Target

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

Zacks

a year ago

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

MT Newswires

a year ago

Needham Initiates Praxis Precision Medicines at Buy With $145 Price Target

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

Zacks

a year ago

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure

Investor's Business Daily

a year ago

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate

Simply Wall St.

a year ago

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Simply Wall St.

a year ago

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

GlobeNewswire

a year ago

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?

MT Newswires

a year ago

Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire

a year ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why

Zacks

a year ago

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why

Praxis Precision Medicines to Participate in Upcoming April Conferences

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care Roundup: Market Talk

The Wall Street Journal

a year ago

Health Care Roundup: Market Talk

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Zacks

a year ago

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Share on Social Networks: